VWM
BBIO icon

Vermillion Wealth Management’s BridgeBio Pharma BBIO Stock Holding History

Vermillion Wealth Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15
Closed -$1.11K – 1626
2026
Q1 		$1.11K Buy
+15
New +$1.09K ﹤0.01% 791

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Vermillion Wealth Management's BBIO Position: Q2 2026 in Review

Vermillion Wealth Management sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 15 shares — an estimated $1.11K sold.

Vermillion Wealth Management first reported a position in BBIO in Q1 2026 and held it in 1 quarter. The position peaked at $1.11K in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Vermillion Wealth Management reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
  • Vermillion Wealth Management sold 15 BridgeBio Pharma shares in Q2 2026, an estimated $1.11K.
  • Vermillion Wealth Management first reported a position in BridgeBio Pharma in Q1 2026 and held it in 1 quarter.
  • Vermillion Wealth Management's BridgeBio Pharma position peaked at $1.11K in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.